11 recruiting. 11 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 11 |
| Phase 2 | 5 | Recruiting 5 |
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| US Zamto-cel Autoimmune Diseases zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | Recruiting | Miltenyi Biomedicine GmbH | 48 | 2026-07-01 | 2026-06-11 |
| Controlling Hyperactive Immunity With Long-lived Lymphocytes QEL-005 - Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA) | Phase 1 / Phase 2 | Recruiting | Quell Therapeutics Limited | 16 | 2026-04-10 | 2026-10-19 |
| A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases XmAb657 - Healthy, Idiopathic Inflammatory Myopathies | Phase 1 | Recruiting | Xencor, Inc. | 60 | 2026-02-24 | 2026-08-03 |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease ALLO-329, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy | Phase 1 | Recruiting | Allogene Therapeutics | 66 | 2025-11-13 | 2026-11-02 |
| A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. PRO-203, Placebo - Healthy Volunteers, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Prolium Bioscience, Inc | 44 | 2025-10-27 | 2026-10-09 |
| A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases BMS-986515, Fludarabine, Cyclophosphamide - Refractory Autoimmune Diseases | Phase 1 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 125 | 2025-09-04 | 2026-07-14 |
| Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs) HN2301 injection - Systemic Lupus Erythematosus, Scleroderma | Phase 1 | Recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 30 | 2025-03-16 | 2026-08-12 |
| A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease CTX112 - SLE (Systemic Lupus), Lupus Erythematosus, Systemic | Phase 1 | Recruiting | CRISPR Therapeutics | 80 | 2025-03-10 | 2026-10-26 |
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 8 | 2024-11-29 | 2025-04-11 |
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NKX019, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | Nkarta, Inc. | 240 | 2024-11-04 | 2026-10-30 |
| Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis Mesenchymal stromal cells, Placebo - Systemic Sclerosis, Digital Ulcer | Phase 1 / Phase 2 | Recruiting | UMC Utrecht | 20 | 2021-10-06 | 2025-09-10 |
Scleroderma, Systemic (9) · Lupus Erythematosus, Systemic (6) · Myositis (5) · Arthritis, Rheumatoid (4) · Autoimmune Diseases (4) · Lupus Nephritis (4) · Dermatomyositis (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Polymyositis (2) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Sclerosis (1)
Skin and Connective Tissue Diseases (11) · Connective Tissue Diseases (10) · Skin Diseases (10) · Immune System Diseases (8) · Musculoskeletal Diseases (7) · Nervous System Diseases (6) · Neuromuscular Diseases (6) · Arthritis (5) · Autoimmune Diseases (5) · Joint Diseases (5) · Muscular Diseases (5) · Rheumatic Diseases (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Glomerulonephritis (4)
Cyclophosphamide (4) · fludarabine (4) · Immunotherapy, Adoptive (1) · tocilizumab (1)
Allogene Therapeutics (1) · CRISPR Therapeutics (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · Miltenyi Biomedicine GmbH (1) · Nkarta, Inc. (1) · Prolium Bioscience, Inc (1) · Quell Therapeutics Limited (1) · Shenzhen MagicRNA Biotechnology Co., Ltd (1) · UMC Utrecht (1) · Xencor, Inc. (1)
United States (5) · Australia (3) · Germany (3) · Spain (3) · China (2) · Brazil (1) · Canada (1) · Czechia (1) · France (1) · Israel (1) · Italy (1) · Mexico (1) · Netherlands (1) · Poland (1) · Romania (1)
Esther Eromosele, MD (1) · Maria Antonietta D'Agostino (1) · Marianne Verhaar, MD, PhD (1) · Salim Mujais (1) · Zhu Chen, MD (1)
2015 (1), 2025 (1)